PTag: 2022

Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx

– PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass. – July 19, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision …

Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx Read More »

Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer

NATICK, Mass. – June 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced the appointment of Vincent Ricci as Chief Financial Officer. Mr. Ricci will lead Pillar Bioscience’s …

Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer Read More »

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology

  Study entitled “Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology” published in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting   NATICK, Mass. – May 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing …

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology Read More »

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel

NATICK, Mass. – March 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced the appointment of Daniel Harma, M.B.A., as Chief Commercial Officer and Christa Adkins, J.D., as General Counsel. Both executives join Pillar Biosciences with more than 20 years of experience in their …

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel Read More »

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NATICK, Mass. – February 10, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that Randy Pritchard, Chief Executive Officer, will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 12:30pm Eastern Time. About …

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Read More »

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory

NATICK, Mass. – January 6, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that its NGS laboratory, located in Natick, Massachusetts, has passed the onsite inspection and received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services’ Centers …

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory Read More »